Steroidal contraceptives and bone fractures in women: Evidence from observational studies

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 7, 2015, Pages

  Lopez, Laureen M ^a   Chen, Mario ^a   Mullins Long, Sarah ^a   Curtis, Kathryn M ^b   Helmerhorst, Frans M ^c  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; GESTAGEN;

BONE MASS; CONTRACEPTION; FEMALE; FOREARM FRACTURE; FRACTURE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SELF REPORT; SYSTEMATIC REVIEW; ADVERSE EFFECTS; AGE; CASE CONTROL STUDY; CHEMICALLY INDUCED; COHORT ANALYSIS; INTRAUTERINE CONTRACEPTIVE DEVICE; OBSERVATIONAL STUDY; TIME;

AGE FACTORS; CASE-CONTROL STUDIES; COHORT STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; FRACTURES, BONE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; MEDROXYPROGESTERONE ACETATE; OBSERVATIONAL STUDIES AS TOPIC; PROGESTINS; TIME FACTORS;

EID: 84957419645     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009849.pub3     Document Type: Review

References (65)

1. Barad D, Kooperberg C, Wactawski-Wende J, Liu J, Hendrix SL, Watts NB. Prior oral contraception and postmenopausal fracture: a Womens' Health Initiative observational cohort study. Fertility and Sterility 2005;84:374-83.
2. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled Clinical Trials. 1998/03/11 1998; Vol. 19, issue 1:61-109.
3. Cooper C, Hannaford P, Croft P, Kay CR. Oral contraceptive pill use and fractures in women: a prospective study. Bone 1993;14(1):41-5.
4. Kaunitz AM, Miller PD, Rice VM, Ross D, McClung MR. Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. Contraception 2006;74(2):90-9.
5. Kaunitz A, Harel Z, Bone H, Ataher Q, Ross D, Arena P, et al. Retrospective cohort study of DMPA and fractures in reproductive age women. http://www.arhp.org/Professional-Education/Annual-Meetings/RH2010/2010-Presentations (accessed 27 January 2012).
6. Lanza LL, McQuay LJ, Rothman KJ, Bone HG, Kaunitz AM, Harel Z, et al. Use of depot medroxyprogesterone acetate contraception and incidence of bone fracture. Obstetrics and Gynecology 2013;121(3):593-600.
7. La Vecchia C, Negri E, Levi F, Baroni JA. Cigarette smoking, body mass and other risk factors for fractures of the hip in women. International Journal of Epidemiology 1991;20(3):671-7.
8. La Vecchia C, Tavani A, Gallus S. Oral contraceptives and risk of hip fractures. Lancet 1999;354(9175):335-6.
9. Parazzini G, Tavani A, Ricci E, La Vecchia C. Menstrual and reproductive factors and hip fractures in post menopausal women. Maturitas 1996;24:191-6.
10. Mallmin H, Ljunghall S, Persson I, Bergstrom R. Risk factors for fractures of the distal forearm: a population-based case-control study. Osteoporosis International 1994;4(6):298-304.
11. Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Use of depot medroxyprogesterone acetate and fracture risk. Journal of Clinical Endocrinology and Metabolism 2010;95(11):4909-16.
12. Memon S, Iversen L, Hannaford PC. Is the oral contraceptive pill associated with fracture in later life? New evidence from the Royal College of General Practitioners Oral Contraception Study. Contraception 2011;84(1):40-7.
13. Michaelsson K, Baron JA, Farahmand BY, Ljunghall S. Influence of parity and lactation on hip fracture risk. American Journal of Epidemiology 2001;153(12):1166-72.
14. Michaelsson K, Baron JA, Farahmand BY, Persson I, Ljunghall S. Oral-contraceptive use and risk of hip fracture: a case-control study. Lancet 1999;353(9163):1481-4.
15. O'Neill TW, Marsden D, Adams JE, Silman AJ. Risk factors, falls, and fracture of the distal forearm in Manchester, UK. Journal of Epidemiology and Community Health 1996;50(3):288-92.
16. Kuopio Osteoporosis Risk Factor and Prevention Study. Kuopio Osteoporosis Risk Factor and Prevention Study. Study Design. http://www.uku.fi/~due2/indexeng.htm (accessed 27 February 2012),.
17. Sirola J, Rikkonen T, Tuppurainen M, Honkanen R, Kroger H. Should risk of bone fragility restrict weight control for other health reasons in postmenopausal women?--A ten year prospective study. Maturitas. 2011/12/20 2012; Vol. 71, issue 2:162-8.
18. Tuppurainen M, Honkanen R, Kröger H, Saarikoski S, Alhava E. Osteoporosis risk factors, gynaecological history and fractures in perimenopausal women--the results of the baseline postal enquiry of the Kuopio Osteoporosis Risk Factor and Prevention Study. Mauritas 1993;17(2):89-100.
19. Tuppurainen M, Kroger H, Saarikoski S, Honkanen R, Alhava E. The effect of previous oral contraceptive use on bone mineral density in perimenopausal women. Osteoporosis International 1994;4(2):93-8.
20. Vessey M, Mant J, Painter R. Oral contraception and other factors in relation to hospital referral for fracture. Findings in a large cohort study. Contraception 1998;57(4):231-5.
21. Vessey MP, Lawless M. The Oxford-Family Planning Association contraceptive study. Clinical Obstetrics and Gynaecology 1984;11(3):743-57.
22. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk in very young women using combined oral contraceptives. Contraception 2008a;78(5):358-64.
23. Vestergaard P, Rejnmark L, Mosekilde L. Oral contraceptive use and risk of fractures. Contraception 2006;73(6):571-6.
24. Vestergaard P, Rejnmark L, Mosekilde L. The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception 2008b;78(6):459-64.
25. Wei S, Venn A, Ding C, Foley S, Laslett L, Jones G. The association between oral contraceptive use, bone mineral density and fractures in women aged 50-80 years. Contraception 2011;84(4):357-62.
26. Albertazzi P, Bottazzi M, Steel SA. Bone mineral density and depot medroxyprogesterone acetate. Contraception 2006;73(6):577-83.
27. Johansson C, Mellstrom D. An earlier fracture as a risk factor for new fracture and its association with smoking and menopausal age in women. Maturitas 1996;24(1-2):97-106.
28. Kruger MC, Kruger IM, Wentzel-Viljoen E, Kruger A. Urbanization of black South African women may increase risk of low bone mass due to low vitamin D status, low calcium intake, and high bone turnover. Nutrition Research 2011;31(10):748-58.
29. Lappe JM, Stegman MR, Recker RR. The impact of lifestyle factors on stress fractures in female Army recruits. Osteoporosis International 2001;12(1):35-42.
30. McGough P, Bigrigg A. Effect of depot medroxyprogesterone acetate on bone density in a Scottish industrial city. European Journal of Contraception and Reproductive Health Care 2007;12(3):253-9.
31. O'Neill TW, Silman AJ, Naves Diaz M, Cooper C, Kanis J, Felsenberg D. Influence of hormonal and reproductive factors on the risk of vertebral deformity in European women. European Vertebral Osteoporosis Study Group. Osteoporosis International 1997;7(1):72-8.
32. Parisi Júnior PD, Chahade WH. Fatores de risco associados à osteoporose em uma população de mulheres brasileiras residentes em São José do Rio Pardo, estado de São Paulo. Revista Brasileira de Reumatologia 2007;47(1):16-24.
33. Pitts SA, Feldman HA, Dorale A, Gordon CM. Bone mineral density, fracture, and vitamin d in adolescents and young women using depot medroxyprogesterone acetate. Journal of Pediatric and Adolescent Gynecology 2012;25(1):23-6.
34. Ruffing JA, Nieves JW, Zion M, Tendy S, Garrett P, Lindsay R, et al. The influence of lifestyle, menstrual function and oral contraceptive use on bone mass and size in female military cadets. Nutrition & Metabolism 2007;4:10.
35. Yang K, McElmurry BJ, Park CG. Decreased bone mineral density and fractures in low-income Korean women. Health Care for Women International 2006;27(3):254-67.
36. Yazdani S, Asli AI, Salemi A, Heidarnia MA, Sarbakhsh P. Determination of Clinical Decision Rule for Estimation of Bone Mineral Density in Women. Medical Principles and Practice 2011;20(5):416-21.
37. Committee on Adolescent Health, Committee on Gynecologic Practice. Depot Medroxyprogesterone Acetate and Bone effects. Obstetrics and Gynecology 2014;123:727-30.
38. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401-6.
39. Centers for Disease Control and Prevention. U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. http://www.cdc.gov/mmwr/pdf/rr/rr59e0528.pdf (accessed 23 January 2012):34.
40. Cleland J, Ali MM. Reproductive consequences of contraceptive failure in 19 developing countries. Obstetrics and Gynecology 2004;104:314-20.
41. Cromer BA, Lazebnik R, Rome E, Stager M, Bonny A, Ziegler J, et al. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. American Journal of Obstetrics and Gynecology 2005;192(1):42-7.
42. Cundy T, Ames R, Horne A, Clearwater J, Roberts H, Gamble G, et al. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. Journal of Clinical Endocrinology and Metabolism 2003;88(1):78-81.
43. Curtis KM, Martins SL. Progestin-only contraception and bone mineral density. Contraception 2006;73:470-87.
44. U.S. Food, Drug Administration. FDA Talk Paper. Black box Warning Added Concerning Long-term Use of Depo-Provera Contraceptive Injection. http://web.archive.org/web/20070809090332/http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html (accessed 24 January 2012).
45. Bartz D, Goldberg AB. Injectable contraceptives. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar MS editor(s). Contraceptive Technology. 20th Edition. New York: Ardent Media, Inc., 2011:209-36.
46. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Medicine 2011;8(5):e1001026.
47. Gourlay ML, Brown SA. Clinical considerations in premenopausal osteoporosis. Archives of Internal Medicine 2004;164:603-14.
48. Guilbert ER, Brown JP, Kaunitz AM, Wagner MS, Bérubé J, Charbonneau L, et al. The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. Contraception 2009;79:167-77.
49. Herrmann M, Seibel MJ. The effects of hormonal contraceptives on bone turnover markers and bone health. Clinical Endocrinology. 2009/09/11 2010; Vol. 72, issue 5:571-83.
50. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. John Wiley & Sons, Ltd, (accessed 30 March 2011).
51. Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858.CD000333.pub2]
52. Isley MM, Kaunitz AM. Update on hormonal contraception and bone density. Reviews in Endocrine & Metabolic Disorders 2011;12(2):93-106.
53. Lopez LM, Grimes DA, Schulz KF, Curtis KM, Chen M. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database of Systematic Reviews 2014, Issue 6. [DOI: 10.1002/14651858.CD006033.pub5]
54. Martins SL, Curtis KM, Glasier AF. Combined hormonal contraception and bone health: a systematic review. Contraception 2006;73:445-69.
55. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;377(9773):1276-87.
56. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
57. Sanchez-Riera L, Wilson N, Kamalaraj N, Nolla JM, Kok C, Li Y, et al. Osteoporosis and fragility fractures. Best Practices & Research in Clinical Rheumatology 2010;24(6):793-810.
58. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
59. STROBE group. STROBE Statement: Strengthening the reporting of Observational studies in Epidemiology. http://www.strobe-statement.org/(accessed 24 April 2012).
60. Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397-404.
61. United Nations, Department of Economic and Social Affairs, Population Division. World Contraceptive Patterns 2013. http://www.un.org/en/development/desa/population/publications/family/contraceptive-wallchart-2013.shtml (accessed 6 July 2015).
62. GA Wells, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 29 November 2011).
63. World Health Organization. WHO statement on hormonal contraception and bone health. Contraception 2006;73:443-4.
64. World Health Organization, Department of Reproductive Healh. Medical eligibility criteria for contraceptive use. Fifth edition - Executive Summary, 2015. http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/(accessed 2 July 2015).
65. World Health Organization, Department of Reproductive Health. Medical eligibility criteria wheel for contraceptive use. 2015. http://www.who.int/reproductivehealth/publications/family_planning/Ex-Summ-MEC-5/en/(accessed 2 July 2015).